Rapid Dose Therapeutics to Showcase Xylistrip, a Dental Product, at Key Tradeshows Across Canada

Rhea-AI Summary

Rapid Dose Therapeutics (CSE: DOSE) has announced its participation in major dental tradeshows across Canada to showcase XyliStrip, an oral dissolving thin film strip powered by QuickStrip technology. The product is designed to address dry mouth (Xerostomia), which affects over 20% of the population and is one of North America's fastest-growing oral health problems.

XyliStrip utilizes RDT's proprietary sublingual thin film strip technology that can be infused with various active ingredients, including Nutraceuticals, Pharmaceuticals, Cannabis, and Nicotine, for rapid bloodstream delivery. The company will present at seven major dental events from April to October 2025, including the Women In Dentistry Symposium, Ontario Society of Periodontists Spring Meeting, and the American Association of Periodontology & Canadian Association of Periodontists Joint Meeting.

Positive

• Addressing large market opportunity with over 20% of population affected by dry mouth
• Proprietary delivery technology capable of multiple active ingredients
• Strategic expansion into dental market through major trade show presence

Negative

• No revenue or sales figures provided
• Product still in showcase phase without proven market acceptance

Burlington, Ontario--(Newsfile Corp. - April 3, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotech Company providing proprietary oral delivery platform via sublingual thin film strip technology, is proud to announce its participation at major dental tradeshows across Canada to showcase and provide samples of an oral dissolving thin film strip called XyliStrip, powered by QuickStrip.

QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including Nutraceuticals, Pharmaceuticals, Cannabis and Nicotine, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. Xylitol is an effective option for dental professionals seeking to support patients experiencing dry mouth (Xerostomia).

"At RDT we are committed to reshaping the future of oral healthcare innovation," said Mark Upsdell, CEO of RDT. "Our participation at these tradeshows will provide dental professionals with a first-hand opportunity to experience XyliStrip and connect directly with our expert team. With cutting-edge science, proprietary technology, and an unwavering commitment to patient care, we are setting a new benchmark for dental care." Xerostomia affects over 20% of the population and is becoming one of the fastest growing oral health problems in North America.

Dry Mouth: Simplified - Oral Health Group

Rapid Dose Therapeutics invites dental professionals and industry stakeholders to visit our booth to learn more about XyliStrip at the following tradeshows:

• Women In Dentistry Symposium- April 4-5,2025| Toronto, ON

• Ontario Society of Periodontists Spring Scientific Meeting- April 4 -5, 2025|Markham,

• Dental Hygiene Practitioners of Ontario- April 11-12, 2025| Rice Lake, Elmhirst.

• ODA The Annual Spring Meeting- May 8-10,2025| Toronto, ON

• Journées dentaires internationales du Québec (JDIQ)- June 2-3, 2025| Montreal, QC

• The Canadian Academy of Restorative Dentistry and Prosthodontics (CARDP) Annual Scientific Meeting- August 21-22,2025| Toronto, ON

• American Association of Periodontology & Canadian Association of Periodontists Joint Meeting- October 16-17, 2025| Toronto, ON

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.

For more information about the Company, visit www.rapid-dose.com.

Contacts:
Mark Upsdell, CEO
investorrelations@rapid-dose.com
416-477-1052

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forwardlooking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the Common Shared States. The securities described in this news release have not been and will not be registered under the Common Shared States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the Common Shared States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247308

FAQ

What is XyliStrip and how does it treat dry mouth (RDTCF)?

XyliStrip is an oral dissolving thin film strip that uses xylitol to treat dry mouth (Xerostomia), delivered through RDT's QuickStrip technology for rapid absorption into the bloodstream.

Which dental trade shows will Rapid Dose Therapeutics (RDTCF) attend in 2025?

RDT will attend 7 major shows including Women In Dentistry Symposium (April), ODA Spring Meeting (May), JDIQ (June), and CARDP Annual Meeting (August) in various Canadian cities.

How prevalent is the dry mouth condition that XyliStrip (RDTCF) targets?

Dry mouth (Xerostomia) affects over 20% of the population and is one of the fastest-growing oral health problems in North America.

What is the delivery mechanism of XyliStrip by Rapid Dose Therapeutics (RDTCF)?

XyliStrip uses QuickStrip technology, a thin orally dissolvable film that delivers active ingredients quickly into the bloodstream for rapid onset.